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IL-17F plays a crucial role in airway inﬂammatory diseases including asthma, but its function has not been fully elucidated. CCL20
is also involved in allergic airway inﬂammation, while its regulatory mechanisms remain to be deﬁned. To further identify a
novel role of IL-17F, the expression of CCL20 by IL-17F in bronchial epithelial cells and the signaling mechanisms involved were
investigated. Bronchial epithelial cells were stimulated with IL-17F, and the levels of CCL20 gene and protein measured, with the
eﬀects of the addition of various kinase inhibitors and siRNAs also investigated. IL-17F signiﬁcantly induced the expression of
CCL20 gene and protein. Pretreatment with inhibitors for MEK1/2, Raf1 and MSK1, and overexpression of a Raf1 dominant-
negative mutant signiﬁcantly diminished IL-17F-induced CCL20 production. Moreover, transfection of the siRNAs targeting
MSK1, p90RSK, and CREB blocked CCL20 expression. These ﬁndings suggest that IL-17F is able to induce CCL20 via Raf1-
MEK1/2-ERK1/2-MSK1/p90RSK-CREB signaling pathway in bronchial epithelial cells. The IL-17F/CCL20 axis may be a novel
pharmacological target for asthma.
1.Introduction
The IL-17 family of cytokines consists of six members, IL-
17 (also called IL-17A), IL-17B, IL-17C, IL-17D, IL-17E (also
called IL-25), and IL-17F [1–5]. We and other groups
discovered human IL-17F [6–8]. We have reported that IL-
17F is capable of inducing several cytokines and chemokines
in bronchial epithelial cells [9–16]. The signaling pathway of
IL-17F has been uncovered. Similar to IL-17A, the receptor
for IL-17F is the heterodimeric complex of IL-17RA and IL-
17RC [17]. Although human IL-17RA binds IL-17A eﬀec-
tively, it binds IL-17F with ∼1000-fold lower aﬃnity [18].
The relative binding aﬃnity of IL-17F to IL-17RC is much
stronger than to IL-17RA. Activation of the receptor by IL-
17F leads to an interaction with Act-1 via the similar ex-
pression to ﬁbroblast growth factor genes, IL-17 receptors,
and TIR (SEFIR) domain [19]. This mediates activation of
TNF receptor-associated factor (TRAF)-6 [19, 20]. More-
over, we have identiﬁed the downstream pathway of IL-
17F receptor signaling. IL-17F activates the Raf1-MEK1/2-
ERK1/2-MSK1/p90RSK-CREB signaling pathway [10–16].
Intheairwayofasthmatics,theexpressionofIL-17Fisclearly
upregulated [6], and is correlated with the disease severity
[6, 21, 22]. We have also demonstrated that a coding-region
variant (H161R) of the IL-17F gene is inversely associated
with asthma and encodes an antagonist for the wild-type IL-
17F [23, 24]. Moreover, a recent study showed that IL-17F
has a possible role in the mechanism of steroid resistance in
asthma [25]. These ﬁndings suggest that IL-17F is one of the
important cytokines involved in the pathogenesis of allergic
airway inﬂammation. IL-17F is derived from activated CD4+
T cells, basophils, and mast cells, three key-eﬀector cell types
involved in asthma [6]. Moreover, IL-17F is produced by a
recently discovered lineage of CD4+ T cells, Th17 cells [26].
Th17 cells selectively produce hallmark cytokines IL-17A
and IL-17F, but not IL-4 and INFγ, and they play a pivotal
role in airway diseases including asthma [27]. In a mouse
model of asthma, Th17 cells-mediated airway inﬂammation
and airway hyperresponsiviness are steroid resistant [28]. In2 Journal of Allergy
asthmatic patients, increased numbers of tissue-inﬁltrating
Th17 cells are observed in the airway [29]. Another study
demonstrated that the number of peripheral Th17 cells is
signiﬁcantly elevated in asthmatic patients compared with
control subjects [30]. These ﬁndings suggest that Th17 cells
have a potential role in the pathogenesis of asthma. However,
it is unclear how Th17 cells traﬃc into the airway of asthma-
tics.
CCL20isaCCchemokineandauniquefunctionalligand
for CCR6. CCL20 is derived from bronchial epithelial cells
in response to several stimuli such as proinﬂammatory cyto-
kines, ambient particulate matter, and the proteolytic aller-
gen Der p1 [31–33]. CCL20 is involved in the pathogenesis
of airway inﬂammatory diseases including asthma. Indeed,
its levels are signiﬁcantly elevated in bronchoalveolar lavage
(BAL) ﬂuid from patients with allergic asthma when com-
pared with control subjects [32]. It is also reported that the
CCL20/CCR6 system plays a pivotal role in allergic airway
responses such as airway resistance, airway eosinophilia, and
production of IL-5 and IgE [34]. In addition, a recent study
demonstrated that human Th17 cells predominantly express
CCR6 [35]. This implies that CCL20 is able to attract Th17
cellsintothesiteofairwayinﬂammationviaCCR6.However,
inducers of epithelium-derived CCL20 in airway inﬂamma-
tion and its regulatory mechanisms have not been fully
understood. To this end, the eﬀects of IL-17F on expression
of CCL20 were investigated. In this study, we demonstrated,
for the ﬁrst time, that IL-17F induces CCL20 in bronchial
epithelial cells via the activation of RafI-MEK1/2-ERK1/2-
MSK1/p90RSK-CREB signaling pathway.
2.MaterialsandMethods
2.1.CellCulture. Two diﬀerentbronchialepithelialcellswere
used in this study. A bronchial epithelial cell line, BEAS-
2B,wasculturedinHanks’F12/DMEM(Bioﬂuids,Rockville,
Md, USA) with 10% heat-inactivated FBS, 100U/mL peni-
cillin, and 100ng/mL streptomycin (Life Technologies-BRL,
Gaithersburg, Md, USA). Normal human bronchial epithe-
lial cells (NHBEs) were purchased from Lonza (Walkersville,
Md,USA),andculturedinbronchialepithelialbasalmedium
according to the manufacturer’s instruction. The cells were
cultured for no more than 3 passages prior to the analysis.
2.2. Analysis of CCL20 Gene Expression. Total RNA was
extracted using RNeasy (Qiagen, Chatsworth, Caif, USA)
from 1 × 106 BEAS-2B cells at 4hrs after stimulation with
10 and 100ng/mL of IL-17F (R&D Systems, Minneapolis,
Minn, USA). cDNAs were synthesized from 500ng of total
RNAusingthecDNAsynthesiskit(TOYOBO,Tokyo,Japan),
followed by real-time PCR. The sequences of real-time PCR
primers for CCL20: forward, 5 -CTGGCTGCTTTGATG-
TCAGT-3 ,r e v e r s e ,5  -CGTGTGAAGCCCACAATAAA-
3 ; G3PDH: forward, 5 -ACCACAGTCCATGCCATCAC-
3 ,r e v e r s e ,5  -TCCACCACCCTGTTGCTGTA-3 . Real-time
PCR was done using a SYBR Green PCR kit (Applied Biosys-
tems, Tokyo, Japan), gene-speciﬁc primers, and an ABI 7700
thermal cycler. The gene expression levels for each amplicon
were calculated using the ΔΔCT method and normalized
against G3PDH gene. The data were shown as fold induction
relative to the control group. The values are expressed as
mean ± SEM (n = 6 experiments).
2.3. Analysis of CCL20 Protein Expression. Cell supernatants
in BEAS-2B cells and NHBEs were harvested from cultures
in the absence or presence of 10 or 100ng/mL of IL-17F at
2, 6, 12, 24, or 48hrs after stimulation. Alternatively, BEAS-
2B cells were also stimulated with 100ng/mL of IL-17A and
IL-17E (IL-25) (R&D Systems) for 24hrs. CCL20 protein
levels in the supernatants were determined with a commer-
cially available ELISA kit (R&D Systems) according to the
manufacturer’s instruction. The values are expressed as
mean ±SEM (n = 6 experiments).
2.4.EﬀectofInhibitorsontheExpressionofCCL20. For analy-
sisofinvolvementoftheRaf1-MEK-ERK1/2-MSK1pathway,
BEAS-2B cells were treated in the presence or ab-sence of
the following kinase inhibitors at varying doses: MEK1/2
inhibitors, PD98059 (Calbiochem, La Jolla, Caif, USA), and
U0126 (New England Bio Labs, Beverly, Mass, USA);
p38MAPK inhibitor, SB202190 (Calbiochem); a Raf1 kinase
inhibitor I (Calbiochem); a JNK inhibitor, SP600125 (Cal-
biochem); MSK1 inhibitors, H89 and Ro318220 (Calbio-
chem); and a vehicle control, DMSO (Me2SO)for1hrbefore
treatment with IL-17F (100ng/mL). The supernatants were
harvested at 24hrs after stimulation for analyses with ELISA.
CCL20 protein levels in the supernatants were determined as
described above. The values are expressed as mean ± SEM
(n = 6 experiments). The total number of cells and cell via-
bility at the end of the culture period for each experiment
were similar among all culture conditions, as determined by
trypan blue exclusion assay, suggesting that the inhibition of
IL-17F-induced CCL20 expression did not result from cyto-
toxicity of those inhibitors (data not shown).
2.5. Overexpression of Dominant Negative Vector for Raf1 and
Ras. The plasmids encoding pCMV-RafS621A Vector (dom-
inant negative mutant of Raf-1) and pCMV-RasN17 Vector
(dominant negative mutant of Ras) cloned into pCMV and a
control vector were purchased from Clontech. The plasmids
werepreparedbyusingtheQiagenplasmidDNApreparation
kit. Transfection experiments utilizing primary epithelial
cells were technically diﬃcult, and an epithelial cell line,
BEAS-2B, was used instead. BEAS-2B cells were cultured in
100mm plates and were transfected by Eﬀectene Reagent
(Qiagen) according to the manufacturer’s instruction. The
cells were selected with 500μg/mL of Geneticin (G418;
Gibco/BRL). After selection, the cells were seeded into 6-well
culture plates. The cells were near conﬂuent, and the super-
natants were then harvested at 24hrs after stimulation with
100ng/mL ofIL-17FforanalyseswithELISA.CCL20 protein
levels in the supernatants were determined as described
above. The values are expressed as mean ± SEM (n = 6e x -
periments).
2.6. Eﬀect of Knockdown of p90RSK, MSK1, and CREB with
siRNA. P r e - d e s i g n e ds i R N A sf o rM S K 1( B i oL a d ) ,p 9 0 R S K ,Journal of Allergy 3
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Figure 1: The expression of CCL20 gene and protein by IL-17F in bronchial epithelial cells. (a) CCL20 gene expression by real-time PCR in
BEAS-2B cells. Real-time PCR was performed as described in Materials and Methods. BEAS-2B cells were stimulated with IL-17F for 4hrs
(n = 6). (c) CCL20 protein levels in supernatants in BEAS-2B cells. ELISA was performed (n = 6). (d) CCL20 protein levels in supernatants
in NHBEs (n = 6). ∗P<. 05 versus medium control. ∗∗P<. 05 versus 10ng/mL of IL-17F-stimulated cells. (e) CCL20 protein levels induced
by IL-17A, IL-17E (IL-25), and IL-17F in supernatants in BEAS-2B cells (n = 6). ∗P<. 05 versus medium control. The values are expressed
as means ±SEM.
CREB and, control siRNAs (Ambion, Tokyo, Japan) were
used. The siRNA transfection into BEAS-2B cells was per-
formed according to the manufacturer’s instruction. The
supernatants were then harvested at 24hrs after stimulation
with 100ng/mL of IL-17F, and subjected for ELISA analyses,
respectively (each n = 6 experiments). CCL20 protein levels
in the supernatants are expressed as mean ±SEM.
2.7. Data Analysis. The statistical signiﬁcance of diﬀerences
wasdeterminedbyanalysisofvariance(ANOVA).Thevalues
areexpressedasmean±SEMfromindependentexperiments.
Any diﬀerence with P values less than 0.05 was considered
signiﬁcant. When ANOVA indicated a signiﬁcant diﬀerence,
the Scheﬀe F-test was used to determine the diﬀerence bet-
ween groups, since it is suitable for testing multiple compari-
sons.
3. Results
3.1. IL-17F Induces the Expression of CCL20. To examine
whetherIL-17FisabletoinduceCCL20expression,BEAS-2B
cells were stimulated with two doses of IL-17F. First, the
levels of CCL20 gene expression were analyzed by real-time
PCR. IL-17F signiﬁcantly induced CCL20 gene expression4 Journal of Allergy
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Figure 2: Eﬀect of PD98059 (PD), U0126, Raf1 kinase inhibitor
I (Raf I), SB202190 (SB), and SP600125 (SP) on CCL20 protein
expression in BEAS-2Bs. The cells were pretreated for 1hr as in-
dicated before the 24-hr stimulation of IL-17F, and then CCL20
protein levels in supernatants were measured by ELISA. The values
are expressed as means ± SEM (n = 6). ∗P<. 05 versus IL-17F-sti-
mulated cells in the absence of the inhibitor. ∗∗P<. 05 versus the
presence of individual inhibitor.
in a dose dependent manner when compared with control
(Figure 1(a)). Next, to analyze the protein expression for
CCL20, the cells were cultured in the presence or absence
of two diﬀerent doses of IL-17F at ﬁve diﬀerent time points.
CCL20 proteins were not detected at the 2hr time point
and were weakly detected at the 6hr time point. However,
its protein levels in supernatants were signiﬁcantly increased
and peaked at the 24hr time point (Figure 1(b)). Similarly,
NHBEs also induced CCL20 expression in response to
IL-17F and showed kinetics similar to those of BEAS-2B
cells (Figure 1(c)). Another IL-17 family cytokine, IL-17A,
showed similar potency in induction of CCL20 expression
compared to IL-17F (Figure 1(d)). In contrast, IL-17E (IL-
25) did not increase its expression in BEAS-2B cells.
3.2. MEK Inhibitors and Raf1 Kinase Inhibitor Inhibit IL-17F-
Induced CCL20 Expression. Pretreatment of the cells for 1hr
with each of the selective MEK inhibitors, PD98059 (10 and
50μM) and U0126 (5 and 10μM), and Raf1 kinase inhibitor
I (1 and 10nM) signiﬁcantly decreased the levels of IL-
17F-induced CCL20 expression in BEAS-2B cells, while 1hr
pretreatment of the cells with vehicle alone (0.1% DMSO)
did not aﬀect CCL20 expression. In addition, the protein
levels of CCL20 were unchanged in IL-17F-treated cells in
the presence of varying doses of a p38 MAPK inhibitor,
SB202190, and a JNK inhibitor, SP600125 (Figure 2). While
induction of CCL20 is partially inhibited by PD98059,
U0126, or Raf1 kinase inhibitor I even at relatively high dose
(50μM, 10μM and 10nM, resp.), the combination of 10μM
of PD98059 and 1nM of Raf1 kinase inhibitor I inhibited, to
a signiﬁcant degree, the production of CCL20 (Figure 2).
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Figure 3: Eﬀect of overexpression of dominant-negative mutants
Raf1 and Ras on CCL20 protein expression in BEAS-2B cells. The
cells overexpressing dominant-negative mutants were stimulated
with IL-17F for 24hrs, and CCL20 protein levels in supernatants
were measured by ELISA. The values are expressed as means±SEM
(n = 6). ∗P<. 05 versus IL-17F-stimulated cells without vector.
3.3. Raf1 and Ras Dominant Negative Mutants Block IL-17F-
Induced CCL20 Expression. Overexpression of Raf1 and Ras
dominant negative mutants in BEAS-2B cells signiﬁcantly
inhibited IL-17F-induced CCL20 expression (Figure 3),
whereas the cells transfected with a control vector showed no
signiﬁcant eﬀect in the level of CCL20 production.
3.4. MSK1 Inhibitors Inhibit IL-17F-Induced CCL20 Expres-
sion. N e x t ,t od e t e r m i n ew h e t h e rM S K 1a ﬀects IL-17F-in-
duced CCL20 expression, the eﬀects of MSK1 inhibitors
were investigated. Pretreatment with two diﬀerent MSK1
inhibitors, Ro-31-8220 and H89, signiﬁcantly suppressed IL-
17F-induced CCL20 expression (Figure 4).
3.5. siRNAs Targeting p90RSK, MSK1, and CREB Inhibit IL-
17F-Induced CCL20 Expression. Finally, the eﬀect of siRNA
targeting p90RSK, MSK1, and CREB on the induction of
CCL20 expression by IL-17F was analyzed. As shown in
Figure 5, its expression by IL-17F was signiﬁcantly inhibited
incellstransfectedwithsiRNAtargetingp90RSK,MSK1,and
CREB, while no signiﬁcant diﬀerence was seen in wild-type
BEAS-2B cells and cells transfected with a control siRNA.
4. Discussion
In this paper, we demonstrated, for the ﬁrst time, that IL-17F
induces the expression of CCL20 in bronchial epithelial cells
through the activation of the Raf1-MEK-ERK1/2-p90RSK/
MSK1-CREB signaling pathway. These ﬁndings suggest that
IL-17F is a potent inducer of CCL20, and the IL-17F/CCR20
axis may provide new insights into the pathophysiology of
asthma.Journal of Allergy 5
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Figure 4:EﬀectofMSK1inhibitors,H89,andRo318220onIL-17F-
induced CCL20. BEAS-2B cells were pretreated for 1hr as indicated
before the 24-hr stimulation of IL-17F, and then CCL20 protein
levels in supernatants were measured by ELISA. The values are ex-
pressed as means±SEM (n = 6). ∗P<. 05 versus IL-17F-stimulated
cells in the absence of the inhibitor.
IL-17F is potentially involved in the pathogenesis of
asthma. Expression of the IL-17F gene is upregulated in BAL
cells from asthmatics following segmental allergen challenge
[6]. Its expression was seen in both bronchial epithelium
and inﬂammatory inﬁltrates in asthmatic patients [21, 22].
Immunocytochemistry showed that IL-17F positive cells in
the subepithelial component and epithelium are signiﬁcantly
elevated in severe asthma compared with control and mild
asthmatic subjects [22]. Furthermore, a polymorphism in
IL-17F gene that results in a loss of lung function mutation
is inversely related to asthma risk [23, 24]. In the mouse
model of asthma, IL-17F is clearly expressed in the lung [36]
and is able to cause pulmonary neutrophilia and provides
an additive eﬀect on antigen-induced allergic inﬂammatory
responses [37]. IL-17F exerts multiple functions. In vitro,w e
have demonstrated that IL-17F stimulates bronchial epithe-
lial cells to induce numerous cytokines and chemokines
such as IL-6, IL-8, IL-11, ENA-78, GROα,G M - C S F ,I P -
10, and IGF-I [6, 9–16]. Furthermore, IL-17F is capable of
inducing several cytokines and chemokines in eosinophils
and lung structural cells including vein endothelial cells and
ﬁbroblasts [8, 38]. These cell types may play crucial roles
in asthma in response to IL-17F. Prior to this study, it was
unknown whether IL-17F aﬀects CCL20 expression. In this
paper, we have found, for the ﬁrst time, that IL-17F is a
potent inducer of CCL20 in bronchial epithelial cells. IL-
17F shows the highest homology with IL-17A among the
IL-17 cytokine family [6]. In this study, IL-17A is also able
to induce CCL20 in bronchial epithelial cells, and this is
consistent with the previous study [39]. Similarly to IL-
17F, IL-17A produced CCL20 via the phosphorylation of
ERK1/2, butnot p38MAPK and JNK. Moreover, IL-17A acti-
vated NF-κB as the downstream of ERK1/2. In contrast, we
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Figure 5: Eﬀect of siRNA for p90RSK, MSK1 and CREB on IL-17F-
induced CCL20 expression. BEAS-2B cells transfected with siRNAs
asindicatedwerestimulatedwithIL-17Ffor24hrs,andthenCCL20
protein levels in supernatants were measured by ELISA. The values
are expressed as means ± SEM (n = 6). ∗P<. 05 versus non-trans-
fected cells.
reported that IL-17F is not able to activate NF-κBi nb r o n -
chial epithelial cells [12]. At present, little is known about
the diﬀerence of signaling pathway for IL-17A and IL-17F.
Additional work is needed to determine their regulatory
mechanisms.
CCL20 has a pivotal role in the pathogenesis of asthma,
and is strongly derived from bronchial epithelial cells in
response to a broad spectrum of asthma-related stimuli
such as pro-inﬂammatory cytokines, ambient particulate
matter, and the proteolytic allergen Der p1 [31–33]. In asth-
matic patients, the level of CCL20 is signiﬁcantly elevated
in BAL ﬂuid when compared with control subjects, and
is more increased after endobronchial allergen provocation
[32, 40]. Moreover, signiﬁcant increase in its expression in
BAL cells from subjects with corticosteroid-resistant asthma
was seen when compared with those with corticosteroid-
sensitive asthma [41]. In the mouse model of asthma, the
CCL20/CCR6 system plays a pivotal role in allergic airway
responses such as airway resistance, airway eosinophilia, and
production of IL-5 and IgE [34]. Interestingly, CCR6 is
predominantly expressed on human Th17 cells, and CCL20
shows chemotactic activity for Th17 cells [35, 42]. Emerging
evidence suggests that Th17 cells are implicated in the
pathogenesis of asthma [27]. Although little is known about
how Th17 cells migrate into the airway, the current study
suggests that IL-17F is able to attract Th17 cells into the site
of airway inﬂammation via, at least partially, the CCL20/
CCR6 system. Taken together, it is possible that IL-17F-
induced epithelial CCL20 attracts Th17 cells into the airway,
andaccumulatedTh17cellsestablishapositivefeedbackloop6 Journal of Allergy
resulting in the recruitment of additional Th17 cells via the
inducing IL-17F. On the other hand, Th17 cells may not
be the major cell source of IL-17F in airway diseases [43].
Indeed, IL-17F is produced by various cell types, such as
basophils, mast cells, monocytes, memory CD4+ T cells,
CD8+ T cells, γδT cells, and NKT cells [6, 8, 44, 45]. Hence,
theseIL-17F-producingcellsmayexertaneﬀectonbronchial
epithelial cells to induce CCL20 and attract Th17 cells
via CCL20/CCR6 system. The IL-17F/CCL20 axis might be
especially important in the pathophysiologic events of aller-
gic airway inﬂammation. However, further in vivo study is
needed to clarify the importance of the IL-17F/CCL20 axis
in asthma.
The signaling pathway of IL-17F has become clearer. We
have previously demonstrated that the expression of IL-17F-
induced cytokines and chemokines is dependent on the acti-
vation of ERK1/2, but not p38MAPK and JNK, in bronchial
epithelial cells [9–13]. The signaling mechanisms of CCL20
expression are not yet fully understood. Here, we have
identiﬁed, for the ﬁrst time, that IL-17F-induced CCL20
expression is through the Raf1-MEK1/2-ERK1/2 pathway,
since Raf1 kinase inhibitor and MEK1/2 inhibitors signif-
icantly decreased its expression. On the other hand, it is
reported that CCL20 expression in bronchial epithelial cells
is mediated by ERK1/2 and p38MAPK [31]. However, in
this study, IL-17F-induced CCL20 expression is mediated
by ERK1/2, but not p38MAPK, since p38MAPK inhibitor
SB202190didnotaﬀectitsexpression.Thisdiﬀerencemaybe
due to the stimuli used. Therefore, ERK1/2 may be a crucial
signaling molecule for the IL-17F-induced CCL20 expres-
sion. These ﬁndings suggest that regulation of the Raf1-
MEK1/2-ERK1/2 pathway may constitute a useful therapeu-
tic target for IL-17F-associated diseases including asthma. In
addition, we have recently identiﬁed that MSK1-CREB and
p90RSK-CREB are two critical signaling pathways of IL-17F
as the downstream elements of the Raf1-MEK1/2-ERK1/2
kinase cascade [14, 15]. These pathways are essential for
CCL20 expression by IL-17F, since MSK1 inhibitors, Ro-
31-8220 and H89, and siRNA targeting MSK1, p90RSK,
and CREB signiﬁcantly diminished its expression. Hence,
CCL20 expression is mediated by the RafI-MEK1/2-ERK1/2-
MSK1/p90RSK-CREB signaling pathway in the case of IL-
17F in bronchial epithelial cells. These data suggest that this
signalingpathwayisapotentialpharmacologicaltargetinthe
IL-17F-mediated airway inﬂammation. However, all inhi-
bitors used in this study did not completely abrogate IL-17F-
induced CCL20 expression. This suggests that the potential
involvement of other signaling pathway. Further study is
needed to clarify a novel signaling molecule of IL-17F.
In conclusion, we identiﬁed a novel function of IL-17F.
IL-17F is capable of inducing CCL20 in bronchial epithelial
cells, and its expression is mediated by the Raf1-MEK1/
2-ERK1/2-MSK1/p90RSK-CREB signaling pathway. Taken
together, the IL-17F/CCL20 axis may have an orchestrating
roleinthepathogenesisofasthmaandcouldpossiblyprovide
a valuable therapeutic target for development of new strate-
gies to treat asthma.
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